Journal
KIDNEY INTERNATIONAL
Volume 90, Issue 4, Pages 740-745Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2016.03.041
Keywords
diagnostics; drug development; imaging; nanoparticles; theranostics; therapeutics
Categories
Funding
- National Institutes of Health New Innovator Award [DP2-HD075698]
- Honorable Tina Brozman Foundation for Ovarian Cancer Research
- Louis V. Gerstner Jr. Young Investigator's Fund
- Frank A. Howard Scholars Program
- Alan and Sandra Gerry Metastasis Research Initiative
- Center for Molecular Imaging and Nanotechnology at Memorial Sloan Kettering Cancer Center, Cycle for Survival
- Byrne Research Fund
- Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center
- Commonwealth Foundation for Cancer Research
- Anna Fuller Fund
- Imaging and Radiation Sciences Program at Memorial Sloan Kettering Cancer Center
- Ovarian Cancer Research Fund (Ann Schreiber Mentored Investigator Award) [370463]
- National Institutes of Health/National Cancer Institute Cancer Center Support Grant [P30 CA008748]
Ask authors/readers for more resources
Nanomedicines have been the subject of great interest for the treatment, diagnosis, and research of disease; however, few specifically address kidney disorders. Nanotechnology can confer significant benefits to medicine, such as the targeted delivery of drugs to specific tissues. Nanomedicines in the clink have increased drug solubility, reduced off-target side effects, and provided novel diagnostic tools. There is an increasing cohort of nanomaterials that may have implications for kidney disease. Here, we review nanomaterial properties that are potentially applicable to kidney research and therapy, and we highlight clinical areas of need that may benefit from kidney nanomedicines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
